Researchers have Uncovered a New Mitochondrial Gene Mutation Related to Charcot-Marie-Tooth Disease
source: pixabay.com

Researchers have Uncovered a New Mitochondrial Gene Mutation Related to Charcot-Marie-Tooth Disease

In a recent study, researchers have uncovered a second gene located within the mitochondria that is associated with Charcot-Marie-Tooth Disease (CMT). This study was recently published in Annals of Neurology. CMT…

Continue Reading Researchers have Uncovered a New Mitochondrial Gene Mutation Related to Charcot-Marie-Tooth Disease
8th Annual Rare Disease Day Genomics Symposium: Dr. Fajgenbaum’s Unique Perspective
source: pixabay.com

8th Annual Rare Disease Day Genomics Symposium: Dr. Fajgenbaum’s Unique Perspective

As part of ongoing events surrounding Rare Disease Day, which is officially recognized on the last day of the month of February, Patient Worthy attended sessions of the 8th Annual…

Continue Reading 8th Annual Rare Disease Day Genomics Symposium: Dr. Fajgenbaum’s Unique Perspective
Green Tea Could Improve Charcot-Marie-Tooth Disease Type 2 Patient Outcomes
source: pixabay.com

Green Tea Could Improve Charcot-Marie-Tooth Disease Type 2 Patient Outcomes

A woman living with Charcot-Marie-Tooth Disease type 2 (CMT2) has experienced symptom improvement following therapy with an anti-inflammatory compound found in green tea. This study was recently published in Medicina.…

Continue Reading Green Tea Could Improve Charcot-Marie-Tooth Disease Type 2 Patient Outcomes
A Gene Therapy Clinical Trial for GM1 Gangliosidosis will Begin This Year in the UK
source: pixabay.com

A Gene Therapy Clinical Trial for GM1 Gangliosidosis will Begin This Year in the UK

Lysogene has just announced that the FDA has approved their Investigational New Drug Application (IND) for a therapy for GM1 gangliosidosis, a rare pediatric condition. The investigational treatment is a…

Continue Reading A Gene Therapy Clinical Trial for GM1 Gangliosidosis will Begin This Year in the UK

Updates Available on Givinostat Clinical Development for DMD

During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…

Continue Reading Updates Available on Givinostat Clinical Development for DMD